Teva Pharmaceutical Industries Limited (NYSE:TEVA) updated its fourth quarter earnings guidance on Thursday. The company provided earnings per share guidance of $0.70-0.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.06. The company issued revenue guidance of $5.3-5.4 billion, compared to the consensus revenue estimate of $5.68 billion.

Several analysts have recently weighed in on the stock. Mizuho reissued a hold rating and issued a $15.00 price target on shares of Teva Pharmaceutical Industries Limited in a research note on Monday. Jefferies Group LLC reissued a hold rating and issued a $26.00 price target (down previously from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Deutsche Bank AG reissued a buy rating and issued a $28.00 price target (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Sanford C. Bernstein cut shares of Teva Pharmaceutical Industries Limited from an outperform rating to a market perform rating and dropped their price target for the company from $42.00 to $28.00 in a research note on Friday, August 4th. Finally, Royal Bank Of Canada reissued an underperform rating and issued a $13.00 price target (down previously from $15.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Monday. Five investment analysts have rated the stock with a sell rating, eighteen have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of Hold and an average target price of $27.83.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its earnings results on Thursday, November 2nd. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.03 by ($0.03). The firm had revenue of $5.61 billion during the quarter, compared to analysts’ expectations of $5.61 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. Teva Pharmaceutical Industries Limited’s revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter last year, the company posted $1.31 earnings per share.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be paid a $0.085 dividend. This represents a $0.34 annualized dividend and a dividend yield of 2.46%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is presently -15.36%.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/11/02/teva-pharmaceutical-industries-limited-teva-updates-q4-earnings-guidance.html.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.